title: The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study.
abstract: Based on the controversial findings of clinical studies regarding the influence of multidrug resistance on mortality, 10 susceptible and 10 multidrug-resistant (MDR) and extended-spectrum beta-lactamase-producing isolates of Escherichia coli were applied to stimulate monocytes isolated from healthy donors. Immune mediators were estimated in supernatants. Four susceptible isolates (Group A) and four MDR isolates (Group B) were used to initiate acute pyelonephritis in 48 rabbits following inoculation of the pathogen into the right renal pelvis. Survival was recorded and blood monocytes were isolated and incubated to estimate the ex vivo release of tumour necrosis factor-alpha (TNFalpha). Release of TNFalpha, interleukin (IL)-6 and IL-8 was higher after 2 h and 4 h of stimulation by MDR isolates compared with susceptible isolates. The opposite occurred for the release of IL-12. Death occurred in 22 rabbits in Group A (91.7%) compared with 12 in Group B (50.0%) (P=0.003). Monocytes isolated at 24 h from Group A rabbits released significantly higher TNFalpha than monocytes from Group B. Tissue bacterial load after animal death was significantly higher in the kidneys of Group A rabbits. It is concluded that susceptible and MDR E. coli stimulate monocytes resulting in a different pattern of release of pro-inflammatory cytokines, which is accompanied by prolonged survival following experimental sepsis by MDR isolates.
authors.affiliation: 4th Department of Internal Medicine, University of Athens, Medical School, Greece.
authors.forename: Magdalini
authors.initials: M
authors.lastname: Bristianou
authors.forename: Charalambos
authors.initials: C
authors.lastname: Panagou
authors.forename: Theodoros
authors.initials: T
authors.lastname: Adamis
authors.forename: Maria
authors.initials: M
authors.lastname: Raftogiannis
authors.forename: Anastasia
authors.initials: A
authors.lastname: Antonopoulou
authors.forename: Michael
authors.initials: M
authors.lastname: Chrisofos
authors.forename: Irene
authors.initials: I
authors.lastname: Galani
authors.forename: Kyriaki
authors.initials: K
authors.lastname: Kanellakopoulou
authors.forename: Thomas
authors.initials: T
authors.lastname: Tsaganos
authors.forename: Evangelos J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D015169:Colony Count, Microbial; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics*; D004926:Escherichia coli / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity*; D004927:Escherichia coli Infections / Q000382:microbiology; D005260:Female; D006801:Humans; D018664:Interleukin-12 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016209:Interleukin-8 / Q000378:metabolism; D007668:Kidney / Q000382:microbiology; D008297:Male; D009000:Monocytes / Q000382:microbiology; D011704:Pyelonephritis / Q000382:microbiology; D011817:Rabbits; D016019:Survival Analysis; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D001618:beta-Lactamases / Q000096:biosynthesis
chemical_list: D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D001618:beta-Lactamases